İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2024

Evaluation of the Effect of Thrombolytic Therapy on Inflammatory Markers in Patients With Acute Pulmonary Embolism

Cureus

YÖKSİS OpenAlex Açık erişim · diamond JCR Q2 Atıf 2 Yüzdelik 63.2% FWCI 0.35
Yıl
2024
ISSN
2168-8184
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

BACKGROUND: Acute pulmonary embolism (APE) is a serious cardiovascular condition characterized by high rates of morbidity and mortality, with inflammation playing a significant role in the severity of the disease and patient outcomes. This study aimed to evaluate the effects of thrombolytic therapy on inflammatory markers in patients diagnosed with APE. STUDY DESIGN AND METHODS: The study was conducted retrospectively on 138 individuals, 69 with pulmonary embolism and 69 without pulmonary embolism (control), who were admitted to Necmettin Erbakan University between January 2019 and April 2023. Demographic information, C-reactive protein (CRP), white blood cells (WBC), neutrophils, platelets, systemic immune-inflammation index (SII), neutrophil-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), multi-inflammatory index (MII-1 and MII-2), hemoglobin, and lymphocyte-to-C-reactive protein ratio (LCR) levels of the cases were evaluated. The inflammatory markers were measured before and after thrombolytic therapy. RESULTS: Levels of CRP, WBC, SII, NLR, and MII-1 were significantly increased in the pulmonary embolism group compared to the control group (p<0.05). In contrast, there was a notable decrease in hemoglobin, MII-2, and LCR levels (p<0.05). In the pulmonary embolism group, levels of CRP, WBC, neutrophils, lymphocytes, hemoglobin, SII, NLR, and MII-1 were significantly lower after thrombolytic treatment compared to their levels before the treatment (p<0.05). Conversely, the post-thrombolytic treatment group exhibited significantly higher levels of platelets, PLR, and LCR compared to the pre-thrombolytic treatment group (p<0.05). CONCLUSIONS: The findings indicate that novel inflammatory markers, such as SII, NLR, and MII, are elevated in APE and tend to decrease following thrombolytic therapy. This suggests that these markers could be useful for monitoring treatment effectiveness and predicting patient outcomes. However, further research is necessary to confirm their clinical utility.

Konular

  • Inflammatory Biomarkers in Disease Prognosis
  • Venous Thromboembolism Diagnosis and Management
  • COVID-19 Clinical Research Studies

Birincil konu Inflammatory Biomarkers in Disease Prognosis

Yazarlar

  1. MUHAMMED FATİH KALELİ NECMETTİN ERBAKAN ÜNİVERSİTESİ
  2. AHMET TAHA ŞAHİN NECMETTİN ERBAKAN ÜNİVERSİTESİ
  3. YAKUP ALSANCAK NECMETTİN ERBAKAN ÜNİVERSİTESİ